Nantahala Capital Management LLC Purchases New Stake in Aytu BioPharma Inc. $AYTU

Nantahala Capital Management LLC acquired a new position in shares of Aytu BioPharma Inc. (NASDAQ:AYTU) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,086,812 shares of the company’s stock, valued at approximately $2,336,646. Nantahala Capital Management LLC owned approximately 0.10% of Aytu BioPharma as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AYTU. Stonepine Capital Management LLC acquired a new stake in shares of Aytu BioPharma in the 2nd quarter worth $1,962,780. AWM Investment Company Inc. purchased a new position in shares of Aytu BioPharma during the 2nd quarter worth $1,332,000. Diadema Partners LP boosted its position in shares of Aytu BioPharma by 12.1% during the 4th quarter. Diadema Partners LP now owns 305,788 shares of the company’s stock valued at $795,000 after acquiring an additional 33,118 shares during the last quarter. Crown Advisors Management Inc. acquired a new position in shares of Aytu BioPharma during the 2nd quarter valued at about $430,000. Finally, Persistent Asset Partners Ltd boosted its position in shares of Aytu BioPharma by 27.2% during the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after acquiring an additional 16,963 shares during the last quarter. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Price Performance

AYTU stock opened at $2.25 on Friday. Aytu BioPharma Inc. has a 52-week low of $1.65 and a 52-week high of $3.07. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27. The stock has a market cap of $24.14 million, a price-to-earnings ratio of -0.49 and a beta of 0.25. The business has a fifty day moving average of $2.23 and a two-hundred day moving average of $2.35.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on AYTU shares. Ascendiant Capital Markets raised their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.75.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.